Annual Report 2024
Department of Strategic Programs
Yoshikatsu Koga, Katsuya Tsuchihara, Yoshinori Ikarashi, Katsuji Aikawa, Shingo Sakashita, Masahiro Yasunaga, Daichi Ota, Mitsuyoshi Yoshimoto, Asuka Kawachi, Ayae Minobe, Yuka Nakamura
Introduction
Gene recombination experiments, biohazard experiments, and chemohazard experiments (special experiments) are performed in the Exploratory Oncology Research & Clinical Trial Center (EPOC). The Department of Strategic Programs has established an appropriate management system for special experiments, an education system for researchers, and a support system for pathological specimen preparation, and has been managing the safety of researchers during special experiments and improving the quality of research.
"Section of Liaisons for Translational Research", "Section of Seeds Selections and Evaluations", "Section of Project Managements", "Section of Public Relations for Translational Research", and "Section of Educations and Career Developments for Translational Research" are established in the Department in order to disseminate various medical seeds through collaboration with domestic/overseas academia/companies to the world from EPOC and the Center for Promotion of Translational Research (CPOT). We also manage the developments of medical seeds and career developments of project managers.
The Team and What We Do
- Approval of gene recombinant experiments and biohazard/chemohazard experiments in accordance with the regulations
In FY2024, 36 studies with gene recombinant experiments and 9 studies with biohazard/chemohazard experiments were approved by the Committee of Gene Recombination and Biohazard/Chemohazard.
- Research support for pathological specimen preparation
In FY2024, we supported pathological specimen preparations, including 1,584 FFPE block preparations, 16,623 thin sections, 2,348 HE stains, 1,983 immunostains, and 92 special stains.
Education
All researchers engaged in the gene recombinant experiments and biohazard/chemohazard experiments are required to attend a lecture on gene recombinant experiments and biohazard/chemohazard experiments according to the Guideline of Gene Recombination and Biohazard/Chemohazard every year.
Future Prospects
The Department of Strategic Programs will manage and support the research in each division of EPOC as a common department of it and a secretariat function of CPOT.
List of papers published in 2024
Journal
1. Yoshimoto M, Hayakawa T, Yamaguchi M, Kimura S, Fujii H. αvβ3 integrin-targeted magnetic resonance imaging in a pancreatic cancer mouse model using RGD-modified liposomes encapsulated with Fe-deferoxamine. PloS one, 19:e0310984, 2024
2. Yoshimoto M, Washiyama K, Ohnuki K, Doi A, Inokuchi M, Kojima M, Miller BW, Yoshii Y, Inaki A, Fujii H. Long-Term Therapeutic Effects of 225Ac-DOTA-E[c(RGDfK)]2 Induced by Radiosensitization via G2/M Arrest in Pancreatic Ductal Adenocarcinoma. Pharmaceutics, 17:9, 2024